



# J. B. Chemicals & Pharmaceuticals Limited

Regd. Office : Neelam Centre, 'B' Wing, 4<sup>th</sup> Floor, Hind Cycle Road, Worli, Mumbai 400 030.  
Corporate Office : Energy IT Park, Unit A2, 3<sup>rd</sup> Floor, Unit A, 8<sup>th</sup> Floor, Appa Saheb Marathe Marg, Prabhadevi, Mumbai – 400 025.  
Phone: 022-2439 5200 / 2439 5500 Fax : 022 – 2431 5331/ 24131 5334  
CIN : L24390MH1976PLC019380 Website: www.jbcpl.com E-mail : secretarial@jbcpl.com

## STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED ON 31<sup>ST</sup> DECEMBER, 2018

(Rs. In lakhs)

| Sl.No. | PART I - Particulars   | Quarter ended    |                  |                  | Nine Month ended   |                  | Year ended         |
|--------|--|------------------|------------------|------------------|--------------------|------------------|--------------------|
|        |  | 31-12-2018       | 30-09-2018       | 31-12-2017       | 31-12-2018         | 31-12-2017       | 31-03-2018         |
|        |  | Unaudited        | Unaudited        | Unaudited        | Unaudited          | Unaudited        | Audited            |
| 1      | Revenue from Operations  | 35,212.05        | 40,427.40        | 30,474.20        | 1,12,236.62        | 93,589.87        | 1,25,473.42        |
| 2      | Other Income   | 1,538.70         | 810.54           | 532.00           | 2,460.96           | 2,416.10         | 3,525.53           |
| 3      | <b>Total Income ( 1+2)</b>   | <b>36,750.75</b> | <b>41,237.94</b> | <b>31,006.20</b> | <b>1,14,697.58</b> | <b>96,005.97</b> | <b>1,28,998.95</b> |
| 4      | <b>Expenses</b>  |                  |                  |                  |                    |                  |                    |
|        | a. Cost of materials consumed  | 11,049.81        | 11,451.18        | 10,081.54        | 33,601.07          | 26,930.51        | 38,701.68          |
|        | b. Purchases of stock-in-trade   | 2,346.28         | 2,907.92         | 2,279.03         | 7,723.59           | 8,576.95         | 9,304.46           |
|        | c. Changes in inventories of finished goods, work-in-progress and stock-in-trade | (1,964.69)       | 110.36           | (1,676.13)       | (2,263.92)         | 120.78           | (38.81)            |
|        | d. Employee benefit expenses   | 6,475.90         | 6,626.02         | 5,310.67         | 19,039.62          | 16,192.63        | 21,730.93          |
|        | e. Finance Costs   | 126.93           | 71.57            | 61.07            | 325.73             | 246.24           | 341.36             |
|        | f. Depreciation and amortization expense   | 1,448.54         | 1,446.62         | 1,425.00         | 4,341.68           | 4,290.55         | 5,594.85           |
|        | g. Other Expenses  | 10,042.28        | 11,119.98        | 8,617.60         | 31,251.70          | 25,423.99        | 35,460.18          |
|        | <b>Total Expenses (4)</b>  | <b>29,525.05</b> | <b>33,733.65</b> | <b>26,098.78</b> | <b>94,019.47</b>   | <b>81,781.65</b> | <b>1,11,094.65</b> |
| 5      | <b>Profit before Tax (3-4)</b>   | <b>7,225.70</b>  | <b>7,504.29</b>  | <b>4,907.42</b>  | <b>20,678.11</b>   | <b>14,224.32</b> | <b>17,904.30</b>   |
| 6      | Tax expenses   | 2,588.35         | 2,360.28         | 1,522.36         | 6,689.70           | 3,630.11         | 5,104.16           |
| 7      | <b>Net Profit/(Loss) after Tax (5-6)</b>   | <b>4,637.35</b>  | <b>5,144.01</b>  | <b>3,385.06</b>  | <b>13,988.41</b>   | <b>10,594.21</b> | <b>12,800.14</b>   |
| 8      | Other Comprehensive Income (net of Tax)  | (61.80)          | (61.81)          | (13.10)          | (185.41)           | (93.79)          | (241.63)           |
| 9      | <b>Total Comprehensive Income after Tax (7+8)</b>                                | <b>4,575.55</b>  | <b>5,082.20</b>  | <b>3,371.96</b>  | <b>13,803.00</b>   | <b>10,500.42</b> | <b>12,558.51</b>   |
| 10     | <b>(i) Earning per share(EPS) (of Rs. 2/- each not annualised)</b>               |                  |                  |                  |                    |                  |                    |
|        | (1) Basic  | 5.64             | 6.16             | 4.03             | 17.02              | 12.62            | 15.24              |
|        | (2) Diluted  | 5.64             | 6.16             | 4.03             | 17.02              | 12.62            | 15.24              |

### NOTES

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on February 8, 2019.
- The auditors have carried out limited review of the financial results for the quarter and nine months ended on December 31, 2018 and they have not expressed modified opinion.
- The Company has one reportable segment viz. Pharmaceuticals.
- The amount of damage caused due to explosion/fire on July 6, 2018 at Company's API unit at Panoli, Gujarat is being assessed by the Insurance Company. The Company believes that the final loss, when determined on due completion of process, will not materially impact the financials.
- Post applicability of Goods and Service Tax (GST) with effect from July 1, 2017, the sales and services which are subjected to GST are disclosed net of GST. Accordingly, the sales and services for the period ended December 31, 2018 is not comparable with the previous corresponding period as the figures for the previous period was inclusive of excise duty.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.

Place : Mumbai  
Date : 08/02/2019

J. B. Mody  
Chairman & Managing Director